Last reviewed · How we verify
Short ragweed pollen allergen extract
Short ragweed pollen allergen extract works by desensitizing patients to short ragweed pollen through subcutaneous injections.
Ragweed pollen allergen extract is a sublingual immunotherapy developed by Merck Sharp & Dohme LLC for treating ragweed-induced rhinoconjunctivitis. It has completed several clinical trials, demonstrating efficacy and safety in both adults and children. The drug is not yet FDA-approved but shows promise as a non-invasive treatment option for allergic rhinitis.
At a glance
| Generic name | Short ragweed pollen allergen extract |
|---|---|
| Also known as | RAGWITEK™, MK-3641 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | allergen extract |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is achieved by gradually increasing the amount of short ragweed pollen in the extract, allowing the body to build up a tolerance and reducing symptoms associated with an allergic reaction. The exact mechanism is not fully understood, but it is believed to involve changes in the immune system's response to the allergen.
Approved indications
- Treatment of short ragweed-induced allergic rhinitis with or without conjunctivitis symptoms
Common side effects
- Injection site reactions
- Allergic reactions
- Headache
- Fatigue
- Nausea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short ragweed pollen allergen extract CI brief — competitive landscape report
- Short ragweed pollen allergen extract updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI